Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial

BACKGROUND: To present longitudinal changes in Functional Assessment of Cancer Therapy-Prostate (FACT-P) scores during 25-week treatment with enzalutamide or placebo in men with progressive metastatic castration-resistant prostate cancer (mCRPC) after chemotherapy in the AFFIRM trial. PATIENTS AND M...

Descripción completa

Detalles Bibliográficos
Autores principales: Cella, D., Ivanescu, C., Holmstrom, S., Bui, C. N., Spalding, J., Fizazi, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269344/
https://www.ncbi.nlm.nih.gov/pubmed/25361992
http://dx.doi.org/10.1093/annonc/mdu510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269344/
https://www.ncbi.nlm.nih.gov/pubmed/25361992
http://dx.doi.org/10.1093/annonc/mdu510

Ejemplares similares